Zydus Lifesciences Global, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA) for the U.S. market. Synthon has a pending abbreviated new drug application in the U.S., seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis. Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product, and thereafter, for the manufacture a...